+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5351780
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squib
  • Genomic Tree
  • Novartis
  • Regeneron
  • Sumitomo Dainippon Pharma
Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global colorectal cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the colorectal cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Colorectal Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:

1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors; BRAF or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
2) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Others
3) By Class: Immunotherapy; Chemotherapy; Others

Companies Mentioned: Merck & Co. Inc; Roche; Sanofi; Amgen; PFIZER

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squib
  • Genomic Tree
  • Novartis
  • Regeneron
  • Sumitomo Dainippon Pharma
1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Colorectal Cancer Drugs

5. Colorectal Cancer Drugs Market Size And Growth
5.1. Global Colorectal Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Colorectal Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Colorectal Cancer Drugs Market Segmentation
6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • BRAF or MEK Inhibitors
  • Tyrosine Kinase (TKI) Inhibitors
  • Immunomodulators
6.2. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others
6.3. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Immunotherapy
  • Chemotherapy
  • Others
7. Colorectal Cancer Drugs Market Regional And Country Analysis
7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Colorectal Cancer Drugs Market
8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Colorectal Cancer Drugs Market
9.1. China Colorectal Cancer Drugs Market Overview
9.2. China Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Colorectal Cancer Drugs Market
10.1. India Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Colorectal Cancer Drugs Market
11.1. Japan Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Colorectal Cancer Drugs Market
12.1. Australia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Colorectal Cancer Drugs Market
13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Colorectal Cancer Drugs Market
14.1. South Korea Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Colorectal Cancer Drugs Market
15.1. Western Europe Colorectal Cancer Drugs Market Overview
15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Colorectal Cancer Drugs Market
16.1. UK Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Colorectal Cancer Drugs Market
17.1. Germany Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Colorectal Cancer Drugs Market
18.1. France Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Colorectal Cancer Drugs Market
19.1. Eastern Europe Colorectal Cancer Drugs Market Overview
19.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Colorectal Cancer Drugs Market
20.1. Russia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Colorectal Cancer Drugs Market
21.1. North America Colorectal Cancer Drugs Market Overview
21.2. North America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Colorectal Cancer Drugs Market
22.1. USA Colorectal Cancer Drugs Market Overview
22.2. USA Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Colorectal Cancer Drugs Market
23.1. South America Colorectal Cancer Drugs Market Overview
23.2. South America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Colorectal Cancer Drugs Market
24.1. Brazil Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Colorectal Cancer Drugs Market
25.1. Middle East Colorectal Cancer Drugs Market Overview
25.2. Middle East Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Colorectal Cancer Drugs Market
26.1. Africa Colorectal Cancer Drugs Market Overview
26.2. Africa Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Colorectal Cancer Drugs Market Competitive Landscape
27.2. Colorectal Cancer Drugs Market Company Profiles
27.2.1. Merck & Co. Inc
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Roche
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Sanofi
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Amgen
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. PFIZER, INC.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Colorectal Cancer Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Colorectal Cancer Drugs Market

30. Colorectal Cancer Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bristol-Myers Squib
  • Genomic Tree
  • Novartis
  • Regeneron
  • Sumitomo Dainippon Pharma
Major players in the colorectal cancer drugs market are Merck & Co. Inc., Roche, Sanofi, Amgen, and Pfizer, Inc.

The global colorectal cancer drugs market is expected to decline from $6.23 billion in 2020 to $6.09 billion in 2021 at a compound annual growth rate (CAGR) of -2.2%. The slow decline is mainly due to the outbreak of COVID-19 that has led to decrease in demand for immunocompromised treatments. The market is expected to reach $6.85 billion in 2025 at a CAGR of 3%.

The colorectal cancer drugs market consists of sale of colorectal cancer drugs. Colorectal cancer (CRC) or bowel cancer, is the cancer affecting large intestine and the rectum. They are also named, colon tumor or rectal cancer depending upon where they begin.

The market covered in this report is segmented by type into vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/pd1 ligand 1 (pd1/pdl1) inhibitors, braf or mek inhibitors, tyrosine kinase (tki) inhibitors, immunomodulators; by distribution channels into hospitals pharmacies, retail pharmacies, others; by class into immunotherapy, chemotherapy, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

The number of colorectal cancer worldwide has been increasing. According to the American Cancer Society (ACS) estimates, there will be around 101,420 new cases of colon cancer and around 44,180 new cases of rectal cancer that would be registered in the USA in 2019. The diagnosed incident cases of colorectal cancer are expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as low-fiber diet, obesity, consumption of alcohol and tobacco amongst others. The increase in number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.

The colorectal cancer industry is governed by regulatory framework laid down by agencies such as US Food and Administration Agency (FDA), European Medicines Agency (EMA), American Society of Clinical Oncology (ASCO), and others. For instance, FDA's recommendation for colorectal cancer drugs industry in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from A to I. The sub-part E deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as colorectal cancer. It also includes guidelines for the monitoring and evaluation of clinical trials of colorectal cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Merck & Co. Inc
  • Roche
  • Sanofi
  • Amgen
  • Pfizer Inc.
  • Abbott Laboratories
  • Taiho Pharma
  • Novartis
  • GlaxoSmithKline
  • Onyx
  • TAKEDA PHARMACEUTICALS
  • Bristol-Myers Squib
  • Sumitomo Dainippon Pharma
  • Array BioPharma
  • Eli Lilly
  • RANDOX LABORATORIES
  • Suzhou Zelgen Biopharmaceuticals
  • Beckman Coulter Inc
  • Regeneron
  • EDP Biotech
  • Genomic Tree
  • Metabiomics Corporation
  • SIEMENS HEALTHCARE
  • Suzhou Zelgen Biopharmaceuticals
  • Sumitomo Dainippon Pharma
  • EPIGENOMICS
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll